Latest News

The 2026 Alzheimer disease drug development landscape highlights a growing shift toward diverse disease-modifying strategies, from amyloid and tau targeting to metabolic and neuroprotective approaches.

FDA’s clearance for PTD802, a first-in-class GPR17 antagonist designed to promote remyelination, enables initiation of a first-in-human phase 1 study in healthy volunteers and advances a novel regenerative approach for multiple sclerosis.

Patients with incident TD incurred annual all-cause healthcare costs nearly double those of matched non-TD controls, driven primarily by inpatient encounters, while fewer than a quarter received any approved treatment.

Bevacizumab becomes approved in Japan for neurofibromatosis type 2 following phase 2 data that suggested potential effects on hearing preservation and tumor volume despite the study not meeting its primary efficacy end point.

The FDA has accepted Regeneron Pharmaceuticals’ new drug application of cemdisiran's for generalized myasthenia gravis under priority review, with a target action date of November 2026.

Here's some of what is coming soon to NeurologyLive® this week.

The associate professor of neurology and neuroscience at the Icahn School of Medicine at Mount Sinai discussed plasma p-tau217 levels association with regional hypometabolism, cortical atrophy, and cognitive impairment in early symptomatic Alzheimer disease.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is adaptive deep brain stimulation!

Matthew Evans, BM, BCh, DPhil, consultant neurologist at Imperial College Healthcare NHS Trust, discusses emerging evidence for immune-mediated small fiber neuropathy, current diagnostic challenges, and the need for better clinical trials and biomarkers.

Phase 3 data showed a 53% reduction in relapse risk versus placebo, and ecopipam could become the first non-antipsychotic option ever approved for Tourette syndrome.

The phase 3 REVITALYZ study assessed whether once-nightly extended-release sodium oxybate can improve excessive daytime sleepiness and other core symptoms of idiopathic hypersomnia.

New preclinical findings suggest that SOM3355's combined VMAT1 inhibition, VMAT2 modulation, and β1-adrenergic antagonism may offer a differentiated approach to managing motor and neuropsychiatric symptoms in Huntington disease.

Irfan Qureshi, MD, chief medical officer at Biohaven, discusses newly reported data on opakalim, highlighting durable seizure control, favorable CNS tolerability, and the investigational agent’s potential role across multiple epilepsy syndromes.